Eli Lilly escalates oral SERD battle with FDA approval for Inluriyo, Verzenio combo

With longer progression-free survival, Jake Van Naarden, president of Lilly Oncology, told Fierce he expects most patients to choose the combination over oral SERD monotherapy.

By FiercePharma · Sep 19, 2026 · via FiercePharma

This is an aggregated industry headline. Read the full story at FiercePharma →

RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.